Latest BioLineRx News & Updates

See the latest news and media coverage for BioLineRx. We track all announcements, press releases, and industry mentions in real time, all in one place.

BioLineRx

Biopharmaceutical company developing oncology and rare disease therapies

biolinerx.com

Headquarters: Modi'in, Israel
Founded year: 2003
Company type: Public company
Number of employees: 40–50
Industry: Pharmaceuticals

Last updated September 25

Latest news about BioLineRx

In short: BioLineRx advanced GLIX1 into Phase 1/2a trials, presented encouraging oncology data, and managed financing and Q2 2026 results.

Company announcements

September 25 BioLineRx

BioLineRx files Form F-1 registration statement

The SEC filing dated Sep 25, 2026, serves as a registration statement for certain foreign private issuers issued by BioLineRx Ltd.

August 31 BioLineRx

BioLineRx reports second quarter financial results and clinical updates

The company posted $4.3 million in losses while advancing its GLIX1 oncology program across multiple tumor types.

August 25 BioLineRx

BioLineRx reports Q2 2026 financial results and GLIX1 update

The company posted a $4.3M net loss, raised $3.75M via offering, and advanced GLIX1 dosing in glioblastoma trials.

August 18 BioLineRx

BioLineRx schedules shareholder meeting for September 23, 2026

The agenda includes director re-elections, share capital increase, and executive compensation approvals. The notice was filed with the SEC on August 18, 2026.

Media coverage

September 10 Financial Times

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro ...

Hemispherian AS is a clinical-stage pharmaceutical company developing first-in-class small-molecule cancer therapies. Its lead program, GLIX1, is being advanced in partnership with BioLineRx for the...

August 31 Investing.com

BioLineRx Q2 2026 revenue flat, GLIX1 development progressing well

The company also expects to conduct an interim futility analysis of the motixafortide pancreatic cancer study later in 2026. Management stated that this analysis will help determine the future direction of the project. Executive Comments CEO Phil Serlin described GLIX1 as a differentiated oncology drug with broad potential. Serlin said: 'GLIX1 is an oral first-in-class small molecule drug with a novel mechanism of action designed to activate TET2 enzymes and induce tumor DNA damage. By restoring TET2 activity, GLIX1 can selectively...'

August 28 Financial Times

BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement

Chardan is acting as the exclusive placement agent for the offering. The aggregate gross proceeds to the Company from the offering are expected to be...

August 25 Yahoo Finance

BioLine Rx Ltd (BLRX) (Q2 2026) Earnings Call Highlights: Advancing GLIX1...

BioLine Rx reports promising preclinical data for its lead candidate GLIX1 while managing a tight cash position and flat royalty revenue.

Never miss news about BioLineRx

Track BioLineRx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

BioLineRx competitors & trending companies

Browse news for competitors to BioLineRx and other trending companies.